Multiple sclerosis (MS) is a chronic disease with an underlying pathology characterized by
inflammation-driven neuronal loss, axonal injury, and demyelination. Bruton's tyrosine …

Multiple Sclerosis is a chronic autoimmune neurodegenerative disorder of the central
nervous system (CNS) that is characterized by inflammation, demyelination, and axonal …

B cells play a central role in the pathogenesis of multiple sclerosis (MS), as demonstrated
through the success of various B cell-depleting monoclonal antibodies. Bruton's tyrosine …

Autoreactive B cell-derived antibodies form immune complexes that likely play a pathogenic
role in autoimmune diseases. In systemic lupus erythematosus (SLE), these antibodies bind …

BTK has become a particularly attractive therapeutic target in autoimmune diseases and B-
cell malignancies, making BTK inhibitors a valuable and important therapeutic option. We …

Bruton's tyrosine kinase (BTK) inhibitors are an emerging class of therapeutics in multiple
sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of which …

Background/Objective (s) Several Bruton's tyrosine kinase inhibitors (BTKis) are in clinical
development for multiple sclerosis (MS). Material (s) and Method (s) In human blood, in vitro …

Bruton's tyrosine kinase (BTK) is a cytoplasmic tyrosine kinase that plays a critical role in the
activation of B cells, macrophages, and osteoclasts. Given the key role of these cell types in …

Background Inhibition of Bruton's tyrosine kinase (BTK) is an emerging multiple sclerosis
(MS) therapy. BTK inhibitors (BTKi) cross the blood-brain barrier and modulate B cells and …

Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as
promising agents in autoimmune disease and B cell malignancies. Bruton's tyrosine kinase …